Search - tctmd.com

Displaying 21 - 40 of 134

Sort: Relevancy | Date

Presentation TCT 2017

Case #2 Resolution: How We Treated a High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Complex Multi-stent PCI or Any PCI for ACS

Presenter: Renato D. Lopes, David J. Moliterno, Sheila Sahni

November 01, 2017

Presentation TCT 2017

Case #2 Introduction: High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Complex Multi-stent PCI or Any PCI for ACS

Presenter: Renato D. Lopes, David J. Moliterno, Sheila Sahni

November 01, 2017

Presentation TCT 2017

Case #1 Resolution: How We Treated a High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Non-Complex PCI for Stable CAD

Presenter: Renato D. Lopes, David J. Moliterno, Amit N Vora

November 01, 2017

Presentation TCT 2017

Case #1 Introduction: High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Non-Complex PCI for Stable CAD

Presenter: Renato D. Lopes, David J. Moliterno, Amit N Vora

November 01, 2017

Presentation TCT 2017

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Samir R. Kapadia, Ioanna Kosmidou

November 01, 2017

Presentation TCT 2017

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Samir R. Kapadia, David J. Moliterno

November 01, 2017

Presentation TCT 2017

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Samir R. Kapadia, Sameer Gafoor

November 01, 2017

Presentation TCT 2017

PIONEER AF: Topline Findings and Practice Implications

Presenter: Robert A. Harrington, Evan A. Stein, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

Is LAA Closure an Alternative to Triple Therapy for All Patients or Just Those at High Bleeding Risk? Current Dataset

Presenter: Samir R. Kapadia, Brian K. Whisenant

November 01, 2017

Presentation TCT 2017

Rationale and Potential Role for LAA Closure in the PCI and ACS Patient

Presenter: Samir R. Kapadia, Ashish Pershad

November 01, 2017

Presentation TCT 2017

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Pascal Vranckx

November 01, 2017

Presentation TCT 2017

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

Presenter: Samir R. Kapadia

November 01, 2017

Presentation TCT 2017

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Renato D. Lopes

November 01, 2017

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

Presenter: Robert A. Harrington, Kurt Huber, Michael D. Ezekowitz

November 01, 2017

Presentation TCT 2017

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic Atrial Fibrillation Patient Who Requires PCI

Presenter: Robert A. Harrington, Kurt Huber, Christopher B. Granger

November 01, 2017

Presentation TCT 2017

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Presenter: Robert A. Harrington, Kurt Huber, Roxana Mehran

November 01, 2017

Presentation TCT 2017

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: Robert A. Harrington, Kurt Huber, Michelle O'Donoghue

November 01, 2017

Presentation TCT 2017

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

Presenter: Robert A. Harrington, Kurt Huber, Didier Carrié

November 01, 2017

Advertisement

Case #2 Resolution: How We Treated a High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Complex Multi-stent PCI or Any PCI for ACS

Case #2 Introduction: High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Complex Multi-stent PCI or Any PCI for ACS

Case #1 Resolution: How We Treated a High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Non-Complex PCI for Stable CAD

Case #1 Introduction: High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Non-Complex PCI for Stable CAD

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

PIONEER AF: Topline Findings and Practice Implications

Is LAA Closure an Alternative to Triple Therapy for All Patients or Just Those at High Bleeding Risk? Current Dataset

Rationale and Potential Role for LAA Closure in the PCI and ACS Patient

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic Atrial Fibrillation Patient Who Requires PCI

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content